Latest News

PDMR dealings

03 June 2019

New York/London, 3 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners...

Read more

Results of Annual General Meeting

31 May 2019

Tiziana announces that at the Annual General Meeting of the Company held at 10:00 a.m. on 31 May 2019 all the resolutions proposed were duly passed.

Read more

Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational

28 May 2019

New York / London May 28, 2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced that it will...

Read more

Notice of Annual General Meeting

07 May 2019

Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

Read more

PDMR dealings

02 May 2019

Tiziana announces that on 1 May 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.

Read more

Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH

01 May 2019

Tiziana announces an update regarding its Investigational New Drug application to the FDA to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.

Read more

Page 2 of 5 Previous Next